What the research found

Researchers identified ANGPTL8, a protein secreted by ageing fat cells, as a measurable contributor to biological ageing and mortality risk. Using data from nearly 10,000 people in a Chinese cohort study, they built predictive models showing that circulating ANGPTL8 levels correlate with estimated biological age and 10-year mortality risk—with effects strongest when levels exceed roughly four times the "optimal" threshold of around 250 ng/L. The protein appears to amplify vulnerability to age-related conditions rather than acting as a standalone risk factor.

In mice, the team demonstrated a causal link by creating animals genetically unable to produce ANGPTL8. These knockout mice showed improved physical function in older age (better grip strength, treadmill endurance, exploratory behaviour), reduced fat senescence, lower systemic inflammation markers, greater muscle mass and fibre quality, and extended lifespan compared to normal controls. Mechanistically, ANGPTL8 works by disrupting the AKT/mTOR/S6K signalling pathway—a well-known regulator of cellular growth and ageing—specifically through binding to AKT2.

Why it matters for you

If you're tracking biomarkers, ANGPTL8 emerges as a potentially useful marker of metabolic health and biological ageing—one that integrates information about fat tissue quality, senescence burden, and systemic inflammation. Unlike inflammatory markers that fluctuate with acute stressors, ANGPTL8 appears stable enough to serve as a biological "clock." It's particularly relevant if you're managing insulin sensitivity, since ANGPTL8 rises with insulin signalling; this suggests that chronically elevated levels may reflect metabolic dysregulation worth addressing through diet, training, or medication.

The findings also reinforce why fat tissue quality matters beyond aesthetics. Senescent adipocytes don't just accumulate—they actively drive systemic inflammation and accelerate ageing. This means that interventions targeting fat mass reduction, metabolic health, or cellular senescence (whether through training intensity, caloric management, or emerging therapies) could theoretically lower ANGPTL8. The AKT/mTOR pathway is relevant too: if you use mTOR inhibitors (like rapamycin) or train in ways that modulate mTOR, ANGPTL8 dynamics might shift.

Caveats

• Mouse lifespan data only: Longevity extension was shown in mice, not humans. Human outcomes are inferred from epidemiological association, not intervention trials.
• Cohort study, not randomised: Human ANGPTL8 associations with mortality are observational; causality cannot be firmly established, and residual confounding is possible.
• No intervention tested: The paper identifies ANGPTL8 as a target but does not demonstrate that lowering it extends human lifespan or improves health outcomes.
• Error rate in age prediction: The "biological age clock" had ~5-year error margins, limiting clinical precision.
• Geographically specific cohort: Data from a Chinese population; generalisability to other ancestries unknown.